CytomX Therapeutics Inc (NASDAQ:CTMX)
| 1.34 Delayed Data As of Nov 28 |  +0.02 / +1.50%Today’s Change | 1.04 Today|||52-Week Range 3.02 | -16.25% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $91.1M |
Company Description
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Contact Information
CytomX Therapeutics, Inc. 151 Oyster Point Boulevard South San Francisco California 94080-1913 |
Employees
Shareholders
| Other institutional | 38.22% |
| Individual stakeholders | 23.99% |
| Mutual fund holders | 10.35% |
Top Executives
| Sean A. McCarthy | Chairman, President & Chief Executive Officer |
| Chris Ogden | Chief Financial & Accounting Officer |
| Marcia P. Belvin | Chief Scientific Officer & Senior Vice President |
| Yu Waye Chu | Chief Medical Officer |
| Lloyd A. Rowland | Secretary, Compliance Officer & General Counsel |
